B-1788 Bosutinib, Free Base, >99%

Synonyms : [SKI-606]

Related Terms : [Bosulif]

  • Size
  • US $
  • £
  • ¥
  • 50 mg
  • 39
  • 35
  • 30
  • 6,100
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 54
  • 49
  • 42
  • 8,400
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 74
  • 68
  • 58
  • 11,500
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 167
  • 153
  • 131
  • 26,000
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 298
  • 274
  • 234
  • 46,400
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 564
  • 518
  • 443
  • 87,800
  • Add to Cart Qty:
  • In stock
  • 5 g
  • 1,195
  • 1,099
  • 940
  • 186,000
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 32 Other Countries
  • M.W. 530.45
  • C26H29Cl2N5O3
  • [380843-75-4]
  • M.I. 14: 10347

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 200 mg/mL; soluble in ethanol at 25 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • LC Labs XP/XR™ — X-ray Proven/X-ray Referenced Structure™. The chemical structure of this new Bosutinib has been unambiguously proven by single-crystal X-ray crytallography.
  • Bosutinib (SKI-606) is a novel tyrosine kinase inhibitor, more potent than imatinib. Bosutinib can overcome not only Bcr-Abl-dependent mechanisms of resistance, but also those that are Bcr-Abl-independent. It is used to treat patients with chronic myelogenous leukemia (CML) who demonstrate resistance to imatinib or develop resistance during treatment. Jabbour, E., et al. "New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance." Semin. Hematol. 44: 25-31 (2007).
  • Bosutinib is an active inhibitor of Bcr-Abl in several chronic myelogenous leukemia cell lines and transfectants. The IC50 values are in the low nanomolar range, which is 10- to 100-fold lower than those obtained with imatinib. Bosutinib has activity in cells where resistance to imatinib resulted from BCR-ABL gene amplification and in three of four Bcr-Abl point mutants examined. In in vivo experiments bosutinib retains activity in models where resistance is not caused by mutations, as well as in cells carrying the Y253F, E255K, and D276G mutations. Bosutinib binds to a different conformation of Bcr-Abl than does imatinib. Puttini, M., et al. "In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells." Cancer Res. 66: 11314-11322 (2006).
  • Bosutinib inhibits tumor cell proliferation, angiogenesis, growth factor expression and Src-mediated signaling pathways in vivo. Jallal, H., et al. "A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo." Cancer Res. 67: 1580-1588 (2007).
  • Bosutinib inhibited src-dependent activation of beta-catenin and blocked beta-catenin nuclear function by reducing its binding to the TCF4 transcription factor and its trans-activating ability in colorectal cancer cells. Coluccia, A.M., et al. "SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling." Cancer Res. 66: 2279-2286 (2006).
  • Bosutinib inhibited Src autophosphorylation in HT29 cells (IC50 = 0.25 µM). Although submicromolar concentrations of bosutinib inhibited HT29 cell colony formation in soft agar, antiproliferative activity on plastic did not correlate with Src inhibition in either HT29 or Colo205 cells (IC50s, 1.5 and 2.5 µM, respectively). Golas, J.M., et al. "SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models." Cancer Res. 65: 5358-5364 (2005).
  • We note that bosutinib is offered for sale by another vendor under the name "Bosutinib Methanoate", by which they probably mean "methanolate" ("methanoate", without the "l", means "formate ester", which is definitely not correct here). This "methanolate" nomenclature is somewhat ambiguous because "methanolate" is often taken to mean "methoxide anion" (also not correct here) rather than "a molecule of neutral methanol included as solvent of crystallization with the primary compound" as presumably intended by this other vendor. The level of solvent or water, if any, in our bosutinib product is found on the Certificate of Analysis for each lot. The presence of solvent or water of crystallization affects the nominal molecular weight but not the biological properties of the bosutinib product.
  • Bosutinib is the active ingredient in the drug product sold under the trade name Bosulif®.  This drug is currently approved in at least one country for use in patients with accelerated or blast phase Philadelphia chromosome-positive chronic myelogenous leukemia with intolerance or resistance to prior therapy.  NOTE: THE BOSUTINIB SOLD BY LC LABORATORIES FOR RESEARCH IS NOT BOSULIF® AND IS NOT FOR HUMAN USE.
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.